Sponsor
Pfizer
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Pfizer appears in 1,519 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)NCT07823608 · lead sponsor · 2026-09-17
RECRUITINGA Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaNCT07772921 · lead sponsor · 2026-08-20
RECRUITINGA Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have ObesityNCT07731139 · lead sponsor · 2026-07-28
RECRUITINGA Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07725809 · lead sponsor · 2026-07-23
RECRUITINGSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287 · lead sponsor · 2026-07-02
RECRUITINGSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066 · lead sponsor · 2026-06-30
RECRUITINGA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731 · lead sponsor · 2026-06-17
RECRUITINGA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549 · lead sponsor · 2026-06-10
RECRUITINGPhase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655 · lead sponsor · 2026-04-08
RECRUITINGA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694 · lead sponsor · 2026-02-11
RECRUITINGSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298 · lead sponsor · 2026-01-30
RECRUITINGSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · lead sponsor · 2026-01-06
RECRUITINGA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · lead sponsor · 2025-12-23
RECRUITINGSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999 · lead sponsor · 2025-12-09
RECRUITINGA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · lead sponsor · 2025-09-29
RECRUITINGThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · lead sponsor · 2025-09-28
RECRUITINGA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · lead sponsor · 2025-08-20
RECRUITINGA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · lead sponsor · 2025-08-05
RECRUITINGThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · lead sponsor · 2025-07-23
RECRUITINGA Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257 · lead sponsor · 2025-06-19
RECRUITINGA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · lead sponsor · 2025-05-20
RECRUITINGA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320 · lead sponsor · 2025-03-06
RECRUITINGAnalysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextNCT06487078 · lead sponsor · 2025-01-20
RECRUITINGA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · lead sponsor · 2024-10-22
RECRUITINGPost Marketing Surveillance(PMS) Study of Lorviqua in KoreaNCT05599412 · lead sponsor · 2023-05-22
RECRUITINGKorean Post-marketing Surveillance for Xeljanz XRNCT04876781 · lead sponsor · 2022-01-12
RECRUITINGSwedish Ibrance Registries Insights (SIRI)NCT04654208 · lead sponsor · 2020-12-15
RECRUITINGStudy of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · lead sponsor · 2020-11-16
RECRUITINGA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977 · lead sponsor · 2018-04-17
RECRUITINGKorea Post Marketing Surveillance (PMS) Study of Talzenna®NCT04982848 · lead sponsor · 2027-06-01
WITHDRAWNA Study to Learn More About Tukysa Once it is Out in the Korean MarketNCT06873191 · lead sponsor · 2027-01-01
NOT_YET_RECRUITINGA Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune DiseasesNCT07782450 · lead sponsor · 2026-11-19
NOT_YET_RECRUITINGTucatinib Continuation StudyNCT07768358 · lead sponsor · 2026-11-06
NOT_YET_RECRUITINGA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or ObesityNCT07845513 · lead sponsor · 2026-11-01
NOT_YET_RECRUITINGA Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNCT07663630 · lead sponsor · 2026-10-23
NOT_YET_RECRUITINGA Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500 · lead sponsor · 2026-10-01
NOT_YET_RECRUITINGA Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)NCT07794774 · lead sponsor · 2026-09-28
NOT_YET_RECRUITINGA Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)NCT07794761 · lead sponsor · 2026-09-28
NOT_YET_RECRUITINGA Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimeNCT07839884 · lead sponsor · 2026-09-21
NOT_YET_RECRUITINGA Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityNCT07792954 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGA Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)NCT07779590 · lead sponsor · 2026-08-19
ACTIVE_NOT_RECRUITINGA Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCNCT07556549 · lead sponsor · 2026-05-18
ACTIVE_NOT_RECRUITINGA Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · lead sponsor · 2026-05-11
ACTIVE_NOT_RECRUITINGA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentNCT07567352 · lead sponsor · 2026-05-01
ACTIVE_NOT_RECRUITINGA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityNCT07508241 · lead sponsor · 2026-03-31
ACTIVE_NOT_RECRUITINGA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · lead sponsor · 2026-02-24
ACTIVE_NOT_RECRUITINGA Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07400679 · lead sponsor · 2026-02-04
COMPLETEDEfficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · lead sponsor · 2025-12-19
ACTIVE_NOT_RECRUITINGA Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489NCT07073820 · lead sponsor · 2025-11-10
ACTIVE_NOT_RECRUITINGA Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060NCT07160738 · lead sponsor · 2025-09-22
COMPLETEDA Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)NCT07086651 · lead sponsor · 2025-07-21
COMPLETEDA Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.NCT06733337 · lead sponsor · 2025-07-11
ACTIVE_NOT_RECRUITINGA Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.NCT06678555 · lead sponsor · 2025-07-04
COMPLETEDA Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseNCT06962969 · lead sponsor · 2025-06-30
COMPLETEDA Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · lead sponsor · 2025-06-30
ACTIVE_NOT_RECRUITINGA Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNCT04889495 · lead sponsor · 2025-05-16
WITHDRAWNA Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487 · lead sponsor · 2025-05-08
TERMINATEDReal World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.NCT06961331 · lead sponsor · 2025-05-07
COMPLETEDA Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesNCT06974734 · lead sponsor · 2025-05-06
TERMINATEDA Study to Learn About the Safety of TALZENNA for the Treatment of Breast CancerNCT06735742 · lead sponsor · 2025-04-12
ACTIVE_NOT_RECRUITINGSponsor roles
lead sponsor928
collaborator591
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.